Activity content starts in:
Industry Webcast
Taking Control: The Urgent Need to Identify and Address Uncontrolled AsthmaIndustry Webcast Sponsored by AstraZeneca; Not for CME/CE Credit
Join us to explore how asthma control is often overestimated and to evaluate the clinical merits of the Asthma Impairment and Risk Questionnaire (AIRQ®) and the Pediatric AIRQ® (Peds-AIRQ®) compared to other asthma control tools. In the United States, asthma imposes a substantial burden, with exacerbations playing a critical role. Due to variable airway inflammation, all patients can be at risk of uncontrolled symptoms and asthma exacerbations. By assessing both symptom impairment and exacerbation risk, the AIRQ® and Peds-AIRQ® can complement current guidelines and facilitate shared decision-making by helping to identify unrecognized asthma morbidity for adults, adolescents, and children with asthma aged 5 years of age and older.
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 9/25/2025
Expiration Date: 9/25/2025
Topics
Faculty
Supporters and Partners
Industry Sponsor
AstraZeneca
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.